Cebix Incorporated Taps New CEO, Raises $31 Million in Advance of Phase IIb Trial
10/17/2012 7:23:45 AM
More...
|
Cebix Incorporated's Once-Weekly Ersatta(TM) for Diabetic Peripheral Neuropathy Well Tolerated in Clinical Study
6/11/2012 11:37:42 AM
More...
|
Cebix Incorporated to Chair Symposium on C-Peptide and the Pathophysiology of Diabetes at European Association for the Study of Diabetes Annual Meeting 2011
9/7/2011 10:47:22 AM
More...
|
Cebix Incorporated's Long-Acting C-Peptide Ersatta™ has Potential in Multiple Chronic Complications of Diabetes
6/27/2011 6:21:00 AM
More...
|